A detailed history of Swiss National Bank transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 107,600 shares of SUPN stock, worth $3.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,600
Previous 107,600 -0.0%
Holding current value
$3.9 Million
Previous $2.88 Million 16.54%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024

SELL
$22.72 - $29.68 $274,912 - $359,128
-12,100 Reduced 10.11%
107,600 $3.11 Million
Q3 2023

Nov 08, 2023

BUY
$27.57 - $32.91 $35,841 - $42,782
1,300 Added 1.1%
119,700 $3.3 Million
Q2 2023

Aug 09, 2023

BUY
$29.91 - $38.73 $53,838 - $69,714
1,800 Added 1.54%
118,400 $3.56 Million
Q1 2023

May 10, 2023

SELL
$34.93 - $42.03 $440,118 - $529,578
-12,600 Reduced 9.75%
116,600 $4.22 Million
Q4 2022

Feb 08, 2023

BUY
$31.09 - $37.88 $77,725 - $94,700
2,500 Added 1.97%
129,200 $4.61 Million
Q3 2022

Nov 09, 2022

BUY
$28.79 - $35.41 $28,790 - $35,410
1,000 Added 0.8%
126,700 $4.29 Million
Q1 2022

May 09, 2022

BUY
$28.51 - $32.9 $245,186 - $282,940
8,600 Added 7.34%
125,700 $4.06 Million
Q3 2021

Nov 08, 2021

BUY
$23.54 - $31.39 $23,540 - $31,390
1,000 Added 0.86%
117,100 $3.12 Million
Q2 2021

Aug 06, 2021

SELL
$26.72 - $33.19 $114,896 - $142,717
-4,300 Reduced 3.57%
116,100 $3.58 Million
Q1 2021

May 07, 2021

BUY
$24.15 - $31.45 $31,394 - $40,885
1,300 Added 1.09%
120,400 $3.15 Million
Q3 2020

Nov 09, 2020

BUY
$20.2 - $25.05 $40,400 - $50,100
2,000 Added 1.71%
119,100 $2.48 Million
Q2 2020

Aug 05, 2020

BUY
$17.09 - $24.89 $263,186 - $383,306
15,400 Added 15.14%
117,100 $2.78 Million
Q1 2020

May 08, 2020

BUY
$14.45 - $24.69 $18,785 - $32,097
1,300 Added 1.29%
101,700 $1.83 Million
Q4 2019

Feb 06, 2020

BUY
$19.93 - $29.13 $39,860 - $58,260
2,000 Added 2.03%
100,400 $2.38 Million
Q3 2019

Nov 12, 2019

BUY
$25.47 - $33.37 $28,017 - $36,707
1,100 Added 1.13%
98,400 $2.7 Million
Q2 2019

Aug 02, 2019

BUY
$29.96 - $38.87 $62,916 - $81,627
2,100 Added 2.21%
97,300 $3.22 Million
Q1 2019

May 10, 2019

BUY
$32.77 - $41.99 $95,033 - $121,771
2,900 Added 3.14%
95,200 $3.34 Million
Q4 2018

Feb 13, 2019

BUY
$30.84 - $49.51 $64,764 - $103,971
2,100 Added 2.33%
92,300 $3.07 Million
Q2 2018

Aug 09, 2018

BUY
$44.1 - $59.85 $79,380 - $107,730
1,800 Added 2.04%
90,200 $5.4 Million
Q1 2018

May 04, 2018

BUY
$37.15 - $46.9 $74,300 - $93,800
2,000 Added 2.31%
88,400 $4.05 Million
Q4 2017

Feb 07, 2018

BUY
$36.4 - $42.6 $105,560 - $123,540
2,900 Added 3.47%
86,400 $3.44 Million
Q3 2017

Nov 03, 2017

BUY
$36.75 - $49.65 $3.07 Million - $4.15 Million
83,500
83,500 $3.34 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.94B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.